In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists IDNNA’s dose as greater than 2.6mg orally and its duration as unknown.[1][2][3] IDNNA produced no effects at tested doses.[1] Higher doses were not assessed.[1]
IDNNA was first described in the scientific literature by Alexander Shulgin and colleagues in 1982.[4] Subsequently, it was described in greater detail by Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) in 1991.[1]
^ abcdShulgin AT (2003). “Basic Pharmacology and Effects”. In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN 978-0-12-433951-4. Archived from the original on 13 July 2025. The N,N-dimethyl homologue of DOI was called IDNNA (2,5-dimethoxy-N,N-dimethyl-4-iodoamphetamine) and, although not active at levels where DOI would be, it led to an extensive series of some 15 mono- and di-N-alkylated amines related to DOI. They were prepared for studies of 131I labelled compounds for rat pharmacology (and eventual 122I PET scanning agents for human studies) but none of them had been clinically explored.
^ abcdTrachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. ISBN 978-3-03788-700-4. OCLC858805226. Archived from the original on 13 November 2025. Retrieved 23 February 2026.{{cite book}}: CS1 maint: bot: original URL status unknown (link)